Skip to main content

Advertisement

Table 1 Characteristics of included studies

From: Prognostic value of performance status in metastatic renal cell carcinoma patients receiving tyrosine kinase inhibitors: a systematic review and meta-analysis

Study Region Study Period No. of patients Follow-up (months) Age (years) Gender (male/female) Tumor histology Type of PS scale Survival NOS
ccRCC non-ccRCC Unknown
Bamias 2010 UK 2006–2009 109 15.8 (0.1–31.5) 59 (30–79) 80/29 100 7 2 ECOG PS OS 7
You 2011 Korea 2006–2009 78 10 59 (34–79) 57/21 78 – – KPS OS, PFS 8
Steffens 2011 Germany 2005–2010 116 21 (9.5–30.3) 61 ± 11.1 79/37 98 18 – ECOG PS OS, PFS 7
Abel 2011 USA 2004–2009 75 15 (10.5–23.0) 60.0 (23–80) 54/21 55 11 9 ECOG PS OS 8
Seidel 2012 Germany 2005–2011 119 NA 61 (27–72) 84/35 106 13 – ECOG PS OS 6
Powles 2014 UK 2006–2009 98 NA 59 (37–78) 75/23 98 – – ECOG PS OS 8
Poprach 2014 Czech 2007–2012 319 15 62 (45–77) 221/98 309 NA NA ECOG PS OS, PFS 7
Park 2014 Korea 2006–2011 83 18 (1–62) 57 (33–80) 60/23 83 – – KPS OS, PFS 7
Kust 2014 Croatia 2008–2013 41 40 (5–48) 60 34/7 41 – – ECOG PS OS, PFS 6
Gore 2015 USA 2005–2007 4543 13.6 (1–71.3) 59 (19–89) 3364/1179 4010 532 1 ECOG PS OS 8
Shin 2015 Korea 2006–2011 182 34.6 (2.3–171.7) 56.9 (33–85) 132/50 182 – – KPS OS, PFS 6
Wang 2016 China 2006–2015 282 37 58 (19–83) 200/82 233 49 – KPS OS 8
Rausch 2016 Germany 2003–2014 88 34.6 (26.4–42.2) 68.8 (30.8–81.5) 69/19 81 6 6 ECOG PS OS 6
Chrom 2016 Poland 2010–2014 266 46.1 (41.2–51.0) 61 (22–85) 180/86 248 18 – ECOG PS OS 6
Artac 2016 Turkey 1998–2012 104 20.8 (1.8–55.5) 57 (29–88) 77/27 65 15 24 KPS PFS 8
Furukawa 2016 Japan 2009–2011 39 15.1 61 (36–77) 27/12 39 – – KPS PFS 7
Hwang 2017 Korea 2007–2013 56 20.2 (1.5–78.3) 60 (37–88) 44/12 51 5 – KPS OS 7
Teishima 2017 Japan 2007–2016 118 NA 64 (40–84) 97/21 102 16 – ECOG PS OS 7
Zucca 2018 Brazil 2008–2014 64 18.5 57 (30–81) 42/22 51 13 – KPS OS 7
  1. ccRCC clear cell renal cell carcinoma, PS performance status, NOS Newcastle-Ottawa score, KPS Karnofsky performance status, ECOG PS Eastern Cooperative Oncology Group performance status, NA not available
Back to article page